Opthea Allowed Key Patent for OPT-302 in United States
Filed with ASX · · 3 pages · English
Earlier from Opthea
- Opthea Completes A$45 Million Capital Raising
- Opthea Successfully Completes Institutional Capital Raising
- Opthea Launches A$45M Financing for Clinical Development
- Opthea Receives EU Regulatory Feedback for OPT-302 Program
- Opthea Completes FDA Meeting to Inform OPT-302 Program
Later from Opthea
- Opthea Presents Further Positive Data from OPT-302 Ph1/2A
- Opthea Appendix 4E and Annual Report 2017
- Opthea Granted Key United States Patent Covering OPT-302
- Opthea Doses First Patient in OPT-302 wAMD Ph2b trial
- Opthea Initiates OPT-302 Diabetic Macular Edema Trial
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea